Trastuzumab + Fluorouracil + Cisplatin + Capecitabine
Phase 3Completed 3 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Sep 1, 2005 → Jun 1, 2010
NCT ID
NCT01041404About Trastuzumab + Fluorouracil + Cisplatin + Capecitabine
Trastuzumab + Fluorouracil + Cisplatin + Capecitabine is a phase 3 stage product being developed by Chugai Pharmaceutical for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01041404. Target conditions include Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01041404 | Phase 3 | Completed |
Competing Products
20 competing products in Gastric Cancer